JP2016518338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518338A5 JP2016518338A5 JP2016503137A JP2016503137A JP2016518338A5 JP 2016518338 A5 JP2016518338 A5 JP 2016518338A5 JP 2016503137 A JP2016503137 A JP 2016503137A JP 2016503137 A JP2016503137 A JP 2016503137A JP 2016518338 A5 JP2016518338 A5 JP 2016518338A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dhcq
- disease
- atorvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- XFICNUNWUREFDP-UHFFFAOYSA-N 2-[4-[(7-chloroquinolin-4-yl)amino]pentylamino]ethanol Chemical compound ClC1=CC=C2C(NC(CCCNCCO)C)=CC=NC2=C1 XFICNUNWUREFDP-UHFFFAOYSA-N 0.000 claims 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791320P | 2013-03-15 | 2013-03-15 | |
| US61/791,320 | 2013-03-15 | ||
| PCT/US2014/029557 WO2014144944A1 (en) | 2013-03-15 | 2014-03-14 | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518338A JP2016518338A (ja) | 2016-06-23 |
| JP2016518338A5 true JP2016518338A5 (enExample) | 2017-04-06 |
| JP6434487B2 JP6434487B2 (ja) | 2018-12-05 |
Family
ID=51529979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503137A Expired - Fee Related JP6434487B2 (ja) | 2013-03-15 | 2014-03-14 | 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9616057B2 (enExample) |
| EP (1) | EP2967062A4 (enExample) |
| JP (1) | JP6434487B2 (enExample) |
| CN (2) | CN108434138A (enExample) |
| WO (1) | WO2014144944A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6434487B2 (ja) * | 2013-03-15 | 2018-12-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン |
| US11501863B2 (en) | 2015-04-09 | 2022-11-15 | Diane R. MOULD | Systems and methods for patient-specific dosing |
| WO2017189686A1 (en) * | 2016-04-27 | 2017-11-02 | The Board Of Regents Of The University Of Texas System | Nurr1 activation in the treatment of metabolic disorders and as an exercise mimetic |
| CN108095767B (zh) * | 2018-01-19 | 2020-10-02 | 无锡海斯凯尔医学技术有限公司 | 组织炎症活动度检测装置 |
| US20200321096A1 (en) * | 2019-03-08 | 2020-10-08 | Diane R. MOULD | Systems and methods for drug-agnostic patient-specific dosing regimens |
| GB2594918A (en) * | 2020-03-30 | 2021-11-17 | Blackhawk Partners Ltd | A pharmaceutical composition comprising hydroxychloroquine, chloroquine, or metabolite thereof |
| EP3892275A1 (en) * | 2020-04-08 | 2021-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hcq or its metabolites for the treatment of lung infections |
| US20230398068A1 (en) * | 2020-09-14 | 2023-12-14 | Philip Morris Products S.A. | Pharmaceutical composition comprising chloroquine and uses thereof |
| WO2022113887A1 (ja) * | 2020-11-27 | 2022-06-02 | 京都府公立大学法人 | 炎症性網膜疾患の判定方法、炎症性網膜疾患治療剤、及び炎症性網膜疾患治療剤のスクリーニング方法 |
| JP2021051776A (ja) * | 2020-12-15 | 2021-04-01 | 株式会社トプコン | 医療情報処理システム及び医療情報処理方法 |
| WO2022256426A1 (en) * | 2021-06-04 | 2022-12-08 | Genovate Biotechnology Co. Ltd. | Treatment of antiphospholipid syndrome using s-hydroxychloroquine |
| CN114689770A (zh) * | 2022-03-02 | 2022-07-01 | 上海长征医院 | 直接检测尿液中羟氯喹及其三种代谢产物的方法及检测试剂盒 |
| CN115068478B (zh) * | 2022-07-22 | 2024-01-09 | 上海医药工业有限公司 | 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA784722A (en) * | 1968-05-07 | W. Dennis Emery | Desethylhydroxychloroquine as an anti-inflammatory agent | |
| US341592A (en) * | 1886-05-11 | Eeubex a | ||
| US3019169A (en) * | 1958-06-23 | 1962-01-30 | Sterling Drug Inc | Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process |
| US3415932A (en) | 1965-05-18 | 1968-12-10 | Sterling Drug Inc | 7 - chloro - 4 - [4-(2-hydroxyethylamino)-1-methylbutylamino]quinoline; anti-inflammatory compositions and method using same |
| US20040229908A1 (en) * | 1999-07-13 | 2004-11-18 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias |
| US20060014786A1 (en) * | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| US20070003636A1 (en) | 2003-01-22 | 2007-01-04 | Francois Mach | Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| US7410975B2 (en) * | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| US8440695B2 (en) | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| FR2898057B1 (fr) * | 2006-03-06 | 2008-07-04 | Centre Nat Rech Scient | Utilisation de composes derives de l'adenine pour le traitement de lupus |
| US20080044390A1 (en) | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
| EP3087988A3 (en) * | 2008-10-06 | 2017-03-01 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| US20120121554A1 (en) * | 2009-05-01 | 2012-05-17 | Edenspace Systems Corporation | Hmg-coa secondary metabolites and uses thereof |
| US20120202849A1 (en) | 2009-10-12 | 2012-08-09 | Anil Pareek | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| KR101813482B1 (ko) * | 2010-11-24 | 2017-12-29 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 | 루푸스의 치료 또는 예방을 위한 조성물 및 방법 |
| WO2014031769A2 (en) | 2012-08-21 | 2014-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases associated with inflammation |
| JP6434487B2 (ja) * | 2013-03-15 | 2018-12-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン |
-
2014
- 2014-03-14 JP JP2016503137A patent/JP6434487B2/ja not_active Expired - Fee Related
- 2014-03-14 CN CN201810522358.9A patent/CN108434138A/zh active Pending
- 2014-03-14 CN CN201480028469.4A patent/CN105228453B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP14763776.3A patent/EP2967062A4/en not_active Withdrawn
- 2014-03-14 US US14/214,307 patent/US9616057B2/en not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/029557 patent/WO2014144944A1/en not_active Ceased
-
2017
- 2017-03-01 US US15/446,860 patent/US9931335B2/en not_active Expired - Fee Related
-
2018
- 2018-02-21 US US15/901,601 patent/US20180311231A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2015143248A5 (enExample) | ||
| JP2007277267A5 (enExample) | ||
| JP2018536710A5 (enExample) | ||
| JP2016523847A5 (enExample) | ||
| WO2011083999A3 (ko) | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
| HRP20210485T1 (hr) | Fitokompleksi iz citrus bergamia | |
| AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| JP2014511891A5 (enExample) | ||
| JP2016517883A5 (enExample) | ||
| RU2017104149A (ru) | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами | |
| MX357446B (es) | Agente terapeutico para dislipidemia. | |
| JP2016511753A5 (enExample) | ||
| Kwon et al. | Cholesterol lowering effects of low-dose statins in Korean patients | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2016509051A5 (enExample) | ||
| JP2006512361A5 (enExample) | ||
| Volkov et al. | Study of therapeutic properties of the prototype injection of a hepatoprotective drug based on flavolignans of silybum marianum | |
| AR101724A1 (es) | COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA | |
| JP2007530528A5 (enExample) | ||
| JP2008513379A5 (enExample) | ||
| RU2017120028A (ru) | Фармацевтическая композиция для лечения гиперлипидимии | |
| RU2021104805A (ru) | Составы с липидными системами, несущими биоактивные соединения для применения в качестве иммунотерапевтического потенцирующего средства или адъюванта для пациентов с раком или иммунологическими нарушениями | |
| RU2018110622A (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ |